Abstract
Conformational change plays an important role in the life of all proteins, starting from when they fold, through their function and often their fate. For an increasing number of proteins inappropriate conformational change leads to a chain of events, which culminate in the deposition of proteinacious aggregates and disease. In this review we consider the current literature on a number of proteins which form part of the Conformational Disease family. We describe here two types of aggregate that can be formed, Type I aggregates are typified by the Serpin superfamily and consist of non-fibrillar polymeric species. Type II aggregates are of the classical fibrillar form formed by a diverse range of proteins. Through biochemical and biophysical analyis of the aggregation reaction of members of these two classes we show that they form these aggregates through highly similar pathways. Essentially, the whole process can be summed up in two key stages. Firstly, the existence of conditions which increase the conformational flexibility of the protein, enabling it to adopt a partially folded state. Secondly, the propensity of this intermediate conformer to form intermolecular linkages leads to multimeric forms, a step often mediated via hydrophobic or β-strand interactions. Our understanding of these structural changes has facilitated the rationale design of specific aggregation inhibitors. We will discuss the successes and pitfalls of such approaches to demonstrate how similar approaches may be applied to any misfolding protein.
Keywords: conformational disease, protein misfolding, serpin, polymerization, drug design
Current Medicinal Chemistry
Title: Promiscuous Beta-Strand Interactions and the Conformational Diseases
Volume: 11 Issue: 4
Author(s): Michelle K.M. Chow, David A. Lomas and Stephen P. Bottomley
Affiliation:
Keywords: conformational disease, protein misfolding, serpin, polymerization, drug design
Abstract: Conformational change plays an important role in the life of all proteins, starting from when they fold, through their function and often their fate. For an increasing number of proteins inappropriate conformational change leads to a chain of events, which culminate in the deposition of proteinacious aggregates and disease. In this review we consider the current literature on a number of proteins which form part of the Conformational Disease family. We describe here two types of aggregate that can be formed, Type I aggregates are typified by the Serpin superfamily and consist of non-fibrillar polymeric species. Type II aggregates are of the classical fibrillar form formed by a diverse range of proteins. Through biochemical and biophysical analyis of the aggregation reaction of members of these two classes we show that they form these aggregates through highly similar pathways. Essentially, the whole process can be summed up in two key stages. Firstly, the existence of conditions which increase the conformational flexibility of the protein, enabling it to adopt a partially folded state. Secondly, the propensity of this intermediate conformer to form intermolecular linkages leads to multimeric forms, a step often mediated via hydrophobic or β-strand interactions. Our understanding of these structural changes has facilitated the rationale design of specific aggregation inhibitors. We will discuss the successes and pitfalls of such approaches to demonstrate how similar approaches may be applied to any misfolding protein.
Export Options
About this article
Cite this article as:
Chow K.M. Michelle, Lomas A. David and Bottomley P. Stephen, Promiscuous Beta-Strand Interactions and the Conformational Diseases, Current Medicinal Chemistry 2004; 11 (4) . https://dx.doi.org/10.2174/0929867043455936
| DOI https://dx.doi.org/10.2174/0929867043455936 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Current concepts in the study of new therapeutic targets and the development of drugs for diseases of the central nervous system
Central nervous system (CNS) diseases are among the leading causes of chronic disability and mortality worldwide. According to the World Health Organization (WHO), neurological disorders affect over 1 billion people, and the cost of their treatment increases annually. However, advances in neuroscience and medicine are enabling fundamentally new approaches to ...read more
Sustainable Molecular Design for Health and Economy: New Directions in Medicinal Chemistry
The evolving landscape of medicinal chemistry is increasingly influenced by the urgent need to reconcile human health priorities with sustainability imperatives and economic feasibility. While drug discovery and therapeutic development pipelines lead to substantive scientific outcomes, they nonetheless remain disproportionately resource-intensive, environmentally taxing, and financially enclosed. In response to these ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Upper Airway Resistance Syndrome
Current Respiratory Medicine Reviews Structural Bioinformatics of Vibrio cholerae Aminopeptidase A (PepA) Monomer
Protein & Peptide Letters Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Genome-Scale Technologies Foster Advances in Neurological and Behavioral Research
Current Psychiatry Reviews Gastroesophageal Reflux Disease (GERD): Current Agents and Future Perspective
Current Pharmaceutical Design Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence
Current Psychiatry Reviews Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator
Medicinal Chemistry Electrophysiological Assessment of Visual Function in Autism Spectrum Disorders
Neuroscience and Biomedical Engineering (Discontinued) Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Gene Therapy by Liver Transplantation and Single Stranded Oligonucleotides (SSOs) in Familial Amyloidotic Polyneuropathy (FAP)
Current Pharmacogenomics Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Current Drug Targets Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase
Medicinal Chemistry Updates on Therapeutics in Clinical Trials for Spinal Cord Injuries: Key Translational Applications of Human Embryonic Stem Cells-Derived Neural Progenitors
CNS & Neurological Disorders - Drug Targets Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Current Topics in Medicinal Chemistry Neurodevelopmental and Neuropsychiatric Perspectives on Respiratory Control: Understanding Congenital and Developmental Disorders
Current Respiratory Medicine Reviews Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry





